Endometrial Cancer Vaccines
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against endometrial cancer and guarantee the finest results for our customers all over the world.
Endometrial Cancer
Endometrial cancer is the most common gynecologic malignancy in developed countries. Preclinical and clinical investigation of immunotherapy for endometrial cancer is not as advanced as for ovarian or cervical cancer. This is probably because the majority of the patients present with grades 1 and 2, low-stage endometrioid tumors, and surgical resection with hysterectomy alone results in cure for these patients. However, for patients with advanced-stage disease and/or high-risk histological subtypes, the prognosis remains poor. Interestingly, approximately 20% to 30% of endometrial cancers are characterized by high microsatellite instability (MSIH) due to genetic or epigenetic defects in components of the DNA mismatch repair pathway. These patients have high somatic mutation and neoantigen load, and potentially high infiltration by T cells. Based on data from colon cancer indicating that patients with MSI-H tumors show improved objective response rate and progression-free survival to checkpoint blockade, there appears to be sound rationale for clinical testing of immune checkpoint inhibitors in other MSI-H tumors such as endometrial cancer.
Therapeutic Vaccines for Endometrial Cancer
Therapeutic cancer vaccination is a form of active immunotherapy. Active immunotherapies stimulate the host’s own immune system to mount an antitumor immune response and induce immunological memory, theoretically producing a durable effect after treatment is stopped. Cancer vaccines exploit the cellular arm of the immune system, inciting a cytotoxic Tlymphocyte response against tumor-associated antigens (TAAs). In concept, cancer vaccines offer the prospect of high specificity, low toxicity, and prolonged activity, though these properties have yet to be reliably translated in clinical practice.
The product of Wilms tumor gene 1 (WT1) has been identified as a TAA with therapeutic potential in endometrial cancer. WT1 is located on chromosome 11p13 and encodes a transcription factor that plays an essential role in the normal development of the urogenital system. It has been detected in 0 % to 79 % of endometrial cancer, depending on the immunohistochemical staining technique.
Cancer testis (CT) antigens, expressed exclusively in male germ cells and placental tissue in healthy adults but ectopically in tumor cells of multiple types of human cancer, have emerged as excellent candidates for therapeutic manipulation. The restricted nature of their expression lends to high tumor-specificity and immunogenicity. To date, several CT antigens have been identified in endometrial cancer.
Creative Biolabs has been developing a range of vaccines against endometrial cancer, including:
- Peptides & Proteins;
- Whole tumor cell;
- Dendritic cell;
- Nucleic-acid based;
- Viral or Bacterial Vectors.
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the endometrial cancer vaccines. If you are interested in our services, please contact us for more details.
Reference
- Longoria, TC. (2015). “Immunotherapy in endometrial cancer - an evolving therapeutic paradigm.” Gynecol Oncol Res Pract 2:11.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
